0.25Open0.25Pre Close0 Volume25 Open Interest120.00Strike Price0.00Turnover116.49%IV51.48%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier28DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type-0.0084Delta0.0003Gamma987.20Leverage Ratio-0.0310Theta-0.0015Rho-8.31Eff Leverage0.0158Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet